A Food and Drug Administration rebuke of televised comments made by Aegerion Pharmaceuticals Inc.’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal. . The emails shed light on the regulator’s oversight of marketing in the Internet age, where comments that might have aired once and been forgotten in the past can now easily be retrieved through a Google search. 